The Immunohistochemistry (IHC) analysis of Ki-67 is the reference test to assess tumor cell proliferation in breast tissue embedded in paraffin according to the International Ki-67 assessment in Breast Cancer Working Group (Dowsett et al., 2011).

Dowsett et al. 12 reviewed that the most common measurement involves immunohistochemical assessment of Ki-67 antigen. Ki-67 is present in all proliferating cells, and its role as a proliferation marker attracts considerable interest. Ki-67 is a nuclear nonhistone protein present in all active phases of cell cycle, except the G 0 phase 13.

The Ki-67 protein (also known as MKI67) is a cellular marker for proliferation, [10] and can be used in immunohistochemistry. It is strictly associated with cell proliferation.

Analysis of Ki-67 expression by immunohistochemistry and qRT-PCR found that a high level of Ki-67 mRNA expression tends to have positive Ki-67 expression, 15 (88.2%), and low level of Ki-67 mRNA expression tends to have negative Ki-67 expression, 7 (53.8%).

2023年9月10日 · For breast cancer, Ki-67 is one of the main tumor biomarkers that your healthcare provider will check for when diagnosing, staging, and monitoring the cancer. A higher level of Ki-67 means that the cancer cells are multiplying at a faster rate.

2021年7月1日 · Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity.

The objectives were to develop a standardized Ki-67 immunohistochemistry (IHC) method for precise, robust, and reproducible assessment of patients with early breast cancer, and utilize this assay to evaluate patients participating in the monarchE study (NCT03155997).

Methods and results: Two hundred and sixty-five infiltrating breast carcinomas were immunostained for Ki67, p53 and bcl-2. The standardized mitotic index (SMI) was determined. Four proliferation groups were based on Ki67 positivity fraction and SMI at optimal cut-off points.

The study aims are to evaluate whether Ki-67 expression detected by immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) may predict clinical response to neoadjuvant chemotherapy in breast cancer.

Ki-67 is a useful immunohistochemistry marker for identifying tumor cells that are proliferating rapidly. Its expression indicates proliferation of tumor and has been proven to predict the aggression of tumor, metastasis, and prognosis in a variety of human cancers, including meningioma, lymphoproliferative disorders, breast tumors, and ...